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ABSTRACT
Late diagnosis limits therapeutic options and survival rate of non-small cell lung 
cancer (NSCLC) patients. Therefore the identification of biomarkers represents an 
emerging medical need. 
A highly sensitive and specific test was developed to identify/quantify a novel/
selective diagnostic biomarker for NSCLC patients, caspase-4. This test was validated 
by using i) plasma from 125 NSCLC patients and 79 healthy (non-pathological) 
subjects, ii) plasma from 139 smokers and iii) from 70 chronic-obstructive pulmonary 
disease (COPD) patients. Caspase-4 quantification was also assessed in the lung 
tumor mass of 98 paired NSCLC patients compared to 10 non-tumor lung tissues (i.e. 
tuberculosis). 
Circulating caspase-4 was detected in both healthy and NSCLC patients; however 
at different range values: 2.603–3.372 ng/ml for NSCLC patients (95% CI) compared 
to 0.3994-0.6219 ng/ml for healthy subjects (95% CI). The sensitivity of the test 
ranged from 97.07% to 100%; the specificity was 88.1% with a positive predictive 
value of 92.54%, accuracy of 95.19% and AUC of 0.971. Smokers (95% CI, 0.3947–
0.6197 ng/ml) and COPD patients (95% CI, 1.703–2.995 ng/ml) showed intermediate 
values of circulating caspase-4. Tissue levels of caspase-4 in the tumor mass showed 
that 72 (72.7%) out of 99 patients were positive. More importantly, higher levels 
(cut-off value = 0.307 ng/ml) of caspase-4 in the tumor mass were associated to 
reduced overall survival (median 0.92 years) compared to NSCLC patients with lower 
levels (median 3.02 years).
We report for the first time caspase-4 as a novel diagnostic and prognostic 
biomarker, opening new therapeutic perspectives for NSCLC patients. 
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INTRODUCTION
Lung cancer is the third common cancer-related 
disease worldwide; however, it is the leading cause of 
cancer-related deaths and it counts more deaths than other 
solid tumors [1]. The number of new cases is expected to 
rise by about 70% over the next two decades; but more 
dramatically, over half of people with lung cancer die 
within one year from time of diagnosis with a survival 
rate less than 10% [1]. 
This dramatic condition is primarily due to the 
lack of early detection tools and to the recognition of 
the symptoms at the sole late stages, combined to poor 
pharmacological efficiency/benefit of the available 
therapeutic approaches. In the absence of a reliable 
screening tool, less than 15% of patients are diagnosed of 
early stage I lung cancer, and less than 15% of all patients 
survive for 5 years after the diagnosis. To date, more than 
80% of patients are ineligible for surgical resection at the 
time of diagnosis, mostly because of the advanced stage 
of the cancer and for the poor general conditions at stage 
III-IV [2, 3]. One of the limitation to early diagnose lung 
cancer is that its initial development is radiologically 
occult. 
Several screening have been developed so far to 
identify biomarkers to provide insights on diagnosis, 
prognosis and response to treatment [4]. Currently, the 
identification of biomarkers has been performed by using 
invasive and non-invasive procedures. In the context of 
lung cancer, the invasive procedures rely on histologic 
confirmation performed on biopsy specimens and on lung 
samples obtained by surgical resection, performed because 
of a high likelihood evidence of lung cancer diagnosis. 
Noninvasive procedures comprise screening of sputum 
cytology, which has been used with limited success [5, 6], 
and low-dose spiral computed tomography (CT) scanning, 
which limitations include high costs and the need for 
repeated scanning [5, 7]. 
Therefore, the research for biomarkers to be easily 
detected in serum by noninvasive procedures at an early 
stage of cancer has become an area of great interest for 
clinicians [8, 9]. 
Several biomarkers for lung cancer have been 
proposed to assist in the screening and early diagnosis 
of this type of cancer. However, limitations related to 
sensitivity and specificity of the (commercially) available 
diagnostic tests have been registered. Therefore, it is 
obvious that the non-invasive identification of selective, 
sensitive and specific biomarker/s represents the emerging 
medical need to avoid late diagnosis and ameliorate the 
personalized therapy with an ensuing higher survival rate 
and better lifestyle of lung cancer patients. 
In this study we found that the circulating/tumor-
associated caspase-4 is a novel diagnostic, predictive 
and prognostic biomarker for non-small cell lung cancer 
(NSCLC) patients.
RESULTS
Circulating caspase-4 is in the plasma of lung 
cancer (non-small cell lung cancer, NSCLC) 
patients
Blood from lung cancer patients, withdrawn before 
thoracic surgery, was tested for the presence of circulating 
caspase-4 by using a custom, not commercially available, 
ELISA kit developed by ImmunePharma S.r.l. (spin-off 
of the University of Salerno, Department of Pharmacy, 
DIFARMA, Italy). 
Healthy subjects, included in this study, did not have 
any altered clinical parameter (i.e. CRP, cholesterol, etc.), 
non chronic respiratory diseases (i.e. non-COPD, non-
Idiopathic Pulmonary Fibrosis (IPF), non-tuberculosis) 
and were non-smokers, in that they could be considered 
non-pathological, healthy (H).
The levels of circulating caspase-4 were 
significantly higher in the plasma of lung cancer patients 
(LC; n = 125) than healthy non-smoker, non-pathological 
subjects (H; n = 79) (Figure 1A). In particular, plasma 
levels of the circulating caspase-4 were five-fold increased 
in lung cancer patients (95% CI, 2.603–3.372 ng/ml) 
compared to healthy subjects (95% CI, 0.3994–0.6219 
ng/ml) (Figure 1A). To note, the circulating levels of 
caspase-4 were significantly low (p < 0.0001) in the 
plasma of patients (n = 10) who were diagnosed of chronic 
respiratory diseases (i.e. tuberculosis, emphysema) (here 
defined as lung pathologies), pathologies that were not 
related to COPD and/or lung cancer, compared to NSCLC 
patients (Figure 1B). These data ruled out the release of 
circulating caspase-4 in pulmonary inflammation. 
To exclude the hypothesis that the observed 
differences could be related to the age, healthy subjects 
and lung cancer patients were stratified as ≤ or ≥ 60 
years old. No statistical differences were observed in the 
levels of caspase-4 in the plasma of lung cancer patients 
who were ≤ or ≥ 60 years old (Table 1). Similarly, no 
differences were observed for healthy subjects who were 
≤ or ≥ 60 years old (Table 1). To note, healthy subjects 
older than 60 still had lower levels of circulating caspase-4 
compared to lung cancer patients older than 60 years old, 
ruling out age-related differences (Table 1). 
In addition, the levels of circulating caspase-4 were 
also evaluated according to the histotype (Figure 1C) and 
stage (Figure 1D) of NSCLC. No statistical differences 
of circulating caspase-4 levels were observed in lung 
cancer patients according to the histotype (Figure 1C) and 
stage (Figure 1D). Moreover, no statistical differences 
were noted between males and females according to the 
histotype (Table 2) and stage (data not shown). 
Based on these data, Receiver Operating 
Characteristic (ROC) curve was performed. Figure 1E shows 
that the area under the curve (AUC) was 0.971, implying 
an accuracy of the test that was higher than 90%, a value 
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above which a biomarker can be defined as an excellent 
diagnostic biomarker. Moreover, we calculated a cut-off 
value according to the Youden’s index [10] which coincided 
with 0.506 ng/ml, that also represented the mean value 
of the circulating caspase-4 at the lower (0.3994 ng/ml) 
and upper (0.6219 ng/ml) 95% confidence interval (CI). 
According to the chosen cut-off, we could calculate false 
and true positive, and true and false negative values. In 
particular, we had: i. False negative (<0.506 ng/ml) = 0; 
ii. False positive (>0.506 ng/ml) = 10; iii. True negative 
(<0.506 ng/ml) = 69; iv. True positive (>0.506 ng/ml) 
= 125. According to MedCalc Software (https://www.
medcalc.org/calc/diagnostic_test.php), the diagnostic test 
had the following features: Sensitivity = 100% (95% CI = 
97.07% to 100%); Specificity = 88.10% (95% CI = 79.19% 
to 94.14%); Positive Likelihood ratio = 7.9; Negative 
Likelihood ratio = 0; Positive predictive value = 92.54%; 
Negative Predictive value = 100%; Accuracy = 95.19% 
(95% CI = 91.3% to 97.7%).
Based on these data, the circulating caspase-4 can 
be proposed as an excellent diagnostic biomarker for 
NSCLC. 
Figure 1: Circulating caspase-4 was in the plasma of NSCLC patients. (A) Levels of caspase-4 were detected in the plasma of 
healthy (H, n = 79) and NSCLC (LC, n = 125) patients. H subjects were non-pathological. LC-derived blood was obtained before surgical 
resection of the tumor mass. Similarly, blood from patients who were not diagnosed of NSCLC or COPD (lung pathologies, n = 10) 
showed low levels of circulating caspase-4 (B). Levels of caspase-4 were analyzed according to the histotype (C) and stage (D) of NSCLC. 
(E) ROC analysis (H subjects vs LC) was performed to define the diagnostic features of caspase-4. Data are expressed as median ± 
interquartile range, showing outliers as dots. One Way ANOVA followed by Bonferroni’s post test was applied to (B, C and D). Mann 
Whitney test was performed for Figure A.
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Circulating caspase-4 is selective for lung cancer 
(non-small cell lung cancer, NSCLC) patients
In order to evaluate whether the circulating 
caspase-4 was present in other types of cancer, we tested 
its values in the blood obtained from patients with some 
solid and liquid tumors. In particular, the levels of the 
circulating caspase-4 were significantly lower in the 
plasma of endometrial carcinoma (KE, n = 12), ovarian 
carcinoma (KO, n = 12), colon carcinoma (K colon, 
n = 16), liver carcinoma (K liver, n = 5), bladder 
carcinoma (K bladder, n = 6) and melanoma (n = 9) 
(Figure 2A). Similarly, liquid tumors were evaluated. 
We found that the circulating caspase-4 was significantly 
lower in chronic lymphocytic leukaemia (CLL, n = 12), 
non-Hodgkin lymphoma (NHL, n = 12) and multiple 
myeloma (MM, n = 12) (Figure 2B).
These data imply that the circulating caspase-4 is 
selectively present in the blood of the sole NSCLC patients 
compared to the other cancer patients we evaluated.
Circulating caspase-4 is detectable in the plasma 
of smokers and COPD patients
In NSCLC patient cohort, 87.2% of lung cancer 
patients were smokers vs 12.8% of non-smokers (Table 3). 
Although, we did not find statistical differences in the 
circulating caspase-4 values between smoker vs non-
smoker lung cancer patients (Table 3), it is widely known 
that smoking represents the highest risk factor for lung 
cancer [11]. Therefore, in order to evaluate the predictive 
power of the circulating caspase-4, the blood of smoking 
healthy subjects (>15 cigarettes/day) (n = 139) was 
tested. We found that the circulating caspase-4 was three-
fold increased (95% CI, 1.331–1.94 ng/ml) compared to 
healthy subjects (95% CI, 0.3947–0.6197 ng/ml), although 
at lower levels than in lung cancer patients (95% CI, 
2.603–3.372 ng/ml) (Figure 3A). Moreover, we did not 
find statistical differences between circulating levels of 
caspase-4 in subjects who were younger (SM < 60, n = 
100) or older (SM > 60, n = 39) than 60 years old (Figure 
3B), further highlighting that the levels of the circulating 
caspase-4 were not age-related as previously reported 
(Table 1). 
Because COPD represents a chronic respiratory 
disease majorly caused by smoking, and that could be a 
risk factor for lung cancer [12], the levels of the circulating 
caspase-4 in the blood of COPD patients (n = 70) were 
also evaluated. We found that the levels of the circulating 
caspase-4 in COPD patients was three times higher (95% 
CI, 1.703–2.995 ng/ml) than healthy subjects (Figure 3C), 
although these levels were still lower than those observed 
in lung cancer patients (Figure 3C). Similarly to smokers, 
we did not have follow-up information for COPD patients. 
Tissue levels of caspase-4 are prognostic for lung 
cancer patients
In order to evaluate the tissue levels of the caspase-4 
(defined as tumor-associated caspase-4), we used the 
ELISA kit developed by ImmunePharma S.r.l.
We found that the levels of caspase-4 were 
significantly increased in NSCLC tissues compared to the 
lung tissues obtained from non-COPD, non-lung cancer 
(ie. Tuberculosis) patients (Figure 4A). In particular, we 
found that 72 (72.7%) out of 99 patients (Tables 4 and 5) 
were positive to caspase-4, according to a cut-off value 
of 0.377 ng/ml, which represented the mean value of the 
95% CI of non-COPD, non-lung cancer tissues. Similarly 
to plasma levels we did not find statistical differences 
among the stages (Figure 4B) and histotypes (Figure 4C). 
Moreover, ROC curve showed that the AUC was 0.7273, 
implying that, although at lower levels than the plasma, 
tissue levels of caspase-4 tested by means of ELISA could 
Table 1: Levels of circulating caspase-4 in subjects older or younger than 60 years old
Healthy (H) Lung Cancer (LC)
Age (years)
 ≥ 60 0.427 (0–1.245) n = 32 2.311 (0.854–15.13) n = 100
 ≤ 60 0.3971 (0–3.05) n = 47 2.28 (1.042–10.25) n = 25
Data are represented as median (median range).
Table 2: Levels of circulating caspase-4 according to lung cancer histotype and gender
Lung Cancer Adenocarcinoma Squamous Other
Gender
Male 2.102 (0.725–15.13) n = 44 2.636 (1.062–5.825) n = 21 3.142 (1.195–8.773) n = 14
Female 2.198 (1.1–7.83) n = 26 2.944 (1.042–5.396) n = 8 2.029 (1226–5.825) n = 12
Data are represented as median (median range).
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represent a novel diagnostic tissue biomarker for NSCLC 
patients (Figure 4D). 
Moreover, in order to understand the prognostic 
value of the tumor-associated caspase-4, we analyzed the 
overall survival rate of NSCLC patients. The levels of 
tumor-associated caspase-4 were defined as low (<0.377 
ng/ml) or high (>0.377 ng/ml) according to the cut-off 
value that derived from the mean of the tissue levels of 
caspase-4 from non-COPD, non-lung cancer patients 
(Figure 4A). High levels of caspase-4 (red line, Figure 5) 
were associated to lower survival rate compared to 
NSCLC patients who had lower levels of caspase-4 
(blue line, Figure 5). Very interestingly, the median 
survival was of 0.925 months for NSCLC patients who 
had higher levels of tissue caspase-4 (>0.377 ng/ml). 
In contrast, NSCLC patients who had lower levels of 
caspase-4 (<0.377 ng/ml) in the tumor mass had longer 
median survival (3.02 years), which was three-fold higher 
compared to patients who had higher levels of caspase-4 
(0.92 years). In particular, 80.8% of NSCLC patients 
(n = 58) had higher expression of caspase-4 compared 
to the patients with lower expression (19.2%, n = 14). 
According to the Log-rank Mantel-Cox and Gehan-
Breslow-Wilcoxon test, the survival rate of NSCLC 
patients who had higher expression of tumor-associated 
caspase-4 was significantly lower (p < 0.0001) than those 
who had lower levels (Table 6). 
Taken altogether, these data imply that the 
circulating, tumor-associated caspase-4 represents a novel 
selective diagnostic and prognostic biomarker. 
DISCUSSION
The identification of biomarkers for lung cancer by 
using non-invasive procedures has become an area of great 
interest in clinic. Currently, solely invasive procedures 
are reliable to define the high likelihood lung cancer 
diagnosis, implying that patients need to undergo thoracic 
surgery before a definite diagnosis, and even worse it has 
to be considered that not all patients that discover to be 
lung cancer patients are operable according to the stage 
and clinical status [13]. 
Figure 2: Circulating caspase-4 was solely present in the plasma of NSCLC patients. Levels of circulating caspase-4 in 
NSCLC were compared to other solid (A) (KE, endometrial cancer, n = 12; KO, ovarian carcinoma, n = 12; K colon, colon carcinoma, n = 
16; K liver, liver carcinoma, n = 5, K bladder, bladder carcinoma, n = 6; melanoma, n = 9) and liquid (B) (chronic lymphocytic leukaemia, 
CLL, n = 12; non-Hodgkin lymphoma, NHL, n = 12; multiple myeloma, MM, n = 12). Data are expressed as median ± interquartile range, 
showing outliers as dots. One Way ANOVA followed by Bonferroni’s post test.
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Our study demonstrates that circulating caspase-4 
represents a novel, highly selective and sensitive 
diagnostic biomarker for NSCLC patients. We found that 
the AUC of the circulating caspase-4 is 0.971 with a high 
accuracy (95%) of diagnosing NSCLC before undergoing 
surgical procedures. Importantly, the diagnostic test has a 
very important feature in that it has high sensitivity and 
positive predictive value to detect lung cancer, implying 
very low false negatives, which nowadays represent 
the real limitation for the diagnostic tools available for 
NSCLC. However, the specificity (true negative vs false 
positive) was lower (88.1%) due to the presence of false 
positives, of whom we do not have a follow-up, implying 
that this value could be different if the subjects were 
followed-up in a time-dependent manner. 
According to clinicaltrials.gov and recent published 
literature [4, 14–17], several biomarkers have been 
proposed for lung cancer diagnosis. In particular: 1. 15-
gene mRNA signature; 2. serum NGAL, MMP-9, NGAL/
MMP-9 complex, and soluble E-cadherin; 3. blood 
biomarkers related to i) hypoxia: Osteopontin (OPN), 
carbonic anhydrase IX (CA-9), and lactate dehydrogenase 
(LDH); ii) inflammation - interleukin 6 (IL-6), IL-8, 
and C-reactive protein (CRP), and α-2-macroglobulin 
(α-2M); and iii) tumor load: Carcinoembryonic antigen 
(CEA) and cytokeratin fragment (CYFRA 21-1); 4. blood 
levels of DCAMLK-1LK-1; 5. serum neuron specific 
enolase (NSE); 6. urine IGFBP-1, sIL-1Ra, CEACAM-1; 
7. circulating microRNAs (miRNAs) such as let-7i-3p 
and miR-154-5p recognized as potential biomarkers 
Figure 3: Circulating caspase-4 was detectable in the plasma of smokers and COPD patients. Levels of circulating 
caspase-4 was analyzed in smokers, n = 139, (A) according to the age (B) (smokers, SM < 60 and SM > 60 years old). Similarly, levels of 
caspase-4 were analyzed in the plasma of COPD patients, n = 70 (C). Data are expressed as median ± interquartile range, showing outliers 
as dots. One Way ANOVA followed by Bonferroni’s post test.
Table 3: Levels of circulating caspase-4 according to smoking status 
Number patients Lung cancer
Smoker 109 (87.2%) 2.279 (0.854–15.13)
Non-smoker 16 (12.8%) 2.764 (1.103–6.600)
Data are represented as median (median range).
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of smoking-related lung cancer; 8. cell-free circulating 
tumor DNA (ctDNA); 9. gene mutations for K-RAS 
and Epidermal Growth Factor Receptor (EGFR) and 
Anaplastic Lymphoma Kinase (ALK); 10. Additional 
biomarkers currently being studied for application in 
cancer treatment include the PIK3CA, HER2, BRAF, 
ROS, RET, NRAS, MET, and MEK1. Nevertheless, 
noninvasive, circulating biomarkers so far under 
investigation and with potential clinical application are 
represented by CYFRA, NSE, CEA, CA 19.9, CA125 and 
circulating miRNA. 
To note, the levels of sensitivity superior to 85% 
(value above which a biomarker could be considered 
as very good/excellent) are reached only after the 
combination of more biomarkers (CYFRA+NSE+CEA
+CA125+CA19.9+ferritin), supporting the fact that each 
Figure 4: Tissue caspase-4 was detectable in the tumor mass of NSCLC patients. (A) Levels of caspase-4 were detected 
in the tumor mass of NSCLC (LC, n = 99) patients compared to lung tissues obtained from non-cancer and non-COPD patients (i.e. 
tubercolosis) (lung pathologies, n = 10). Levels of tumor-associated caspase-4 were analyzed according to the stage (B) and histotype (C) 
(D) ROC analysis (lung pathologies vs LC) was performed to define the diagnostic features of caspase-4 starting from tissue samples. Data 
are expressed as median ± interquartile range, showing outliers as dots. One Way ANOVA followed by Bonferroni’s post test was applied.
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single biomarker has very low features of picking true 
positives. Therefore the combination of these available 
biomarkers has very low probability of diagnosing 
NSCLC in an accurate and efficient manner [18]. In 
addition, all the above biomarkers are common to other 
malignancies [18, 19], implying a non-selective presence, 
which could represent a major pitfall in case the patients 
undergo clinical evaluation for unknown unhealthy status. 
Another recently developed diagnostic/predictive test for 
eight common tumors, including NSCLC, is CancerSeek 
[20], based on multi-analyte blood non-invasive test. 
In the latter paper, NSCLC patients (n = 104) were 
screened according to the levels of the well-known gene 
mutations, such as K-Ras, p53, etc, versus protein levels, 
Table 4: Positive vs negative staining of tissue caspase-4 according to the stage (IA-IB, IIA-IIB, IIA-IV)
CASP4
Negative Positive
Stage
IA-IB 12 41
IIA-IIB 12 21
IIIA-IV 3 10
Total 27 72
Table 5: Positive vs negative staining of tissue caspase-4 according to the histotype (ADC = adenocarcinoma, SQU = 
squamous, other carcinoma)
CASP4
Negative Positive
Histotype
ADC 17 38
SQU 4 18
Other 6 16
Total 27 72
Figure 5: NSCLC patients with higher levels of caspase-4 in the tumor mass showed lower survival rate. Tissue levels 
of caspase-4 were correlated to the available survival rate of NSCLC patients (n = 73). In particular, 59 NSCLC patients (80.8%) showed 
levels of tumor-associated caspase-4 higher than the cut-off (0.377 ng/ml); 14 NSCLC patients (19.2%) showed lower levels of caspase-4 
than the chosen cut-off. Median survival of patients with high expression (red line) was 0.92 years vs median survival of patients with 
lower expression (blue line), 3.02 years. Log-rank Mantel-Cox and Wilcoxon test were performed to statistically analyze the survival rate 
between the two groups.
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such as CEA, CA-125, CA19-9, osteopontin, etc. [20]. To 
our opinion, one great limitation of this test for NSCLC 
are the false negative values: 43 patients diagnosed of 
lung cancer were not positive to the multi-analyte blood 
test, implying lower sensitivity of the diagnostic multi-
analyte test for NSCLC. Instead, our diagnostic tool 
proved that, although the false positive values (n = 10 
out of 79 healthy subjects), patients clinically diagnosed 
of NSCLC were all positive to the screening, with no 
false negative results. False negatives represent the real 
limitation for a diagnostic biomarker in that a subject will 
show symptoms and obtain the final diagnosis at a late 
stage, limiting both surgery and therapeutic procedures. 
Moreover, in our study, circulating caspase-4 was solely 
detected at high levels (above the cut-off, 0.506 ng/ml) 
in NSCLC patients compared to some solid and liquid 
cancer patients, implying high selectivity of the test. 
Noteworthy, our diagnostic tool compared to the above 
described has higher levels of sensitivity, specificity and 
accuracy, with a positive likelihood of 7.9 and positive 
predictive value of 92.54. These results imply that a 
patient undergoing several screens to define a mass 
identified in the lung first by radiography and then by 
CT scan, could be easily identified at an early stage by 
evaluating the circulating levels of caspase-4. 
Other non-invasive procedures comprise screening 
of sputum cytology, which has been used with limited 
success [5, 6], and low-dose spiral computed tomography 
(CT) scanning, which limitations include high costs and 
the need for repeated scanning [5, 7]. In the latter case, 
low-dose CT scan has been associated to the detection 
of around 21 miRNA to increase the sensitivity of the 
diagnostic test [21]. The presence of specific miRNA is 
correlated to lung cancer diagnosis [22], however, it still 
remains to understand whether the presence or not of one 
these miRNAs could change sensitivity and specificity of 
the diagnostic test. 
Another emerging area of interest is represented 
by the analyses of the exhaled metabolites by means of 
mass spectrometry [23]. In this case, it is likely that daily 
status, food intake, lifestyle (ie. alcohol usage) could 
alter the levels of metabolites that might be non-specific 
for lung malignancy. In contrast, we found that besides 
the circulating, tissue levels of caspase-4 could represent 
a novel manner to diagnose lung cancer, although the 
ROC curve of the ELISA test on tissues was not as high 
as in the plasma. Nevertheless, we found that patients 
that were positive (high expression, >0.377 ng/ml) to 
caspase-4 had lower survival rate than negative (low 
expression, <0.377 ng/ml) patients. Median survival 
Table 6: Statistical analysis for survival rate of NSCLC according to high (>0.377 ng/ml) and low (<0.377 ng/ml) 
expression of tumor-associated caspase-4
Comparison of Survival Curves
Log-rank (Mantel-Cox) Test
 Chi square 27.84
 df 1
 P value P < 0.0001
 P value summary ***
 Are the survival curves sig different? Yes
Gehan-Breslow-Wilcoxon Test
 Chi square 27.76
 df 1
 P value P < 0.0001
 P value summary ***
 Are the survival curves sig different? Yes
Median survival
>0.377 0.9250
<0.377 3.028
 Ratio 0.3055
 95% CI of ratio –0.2529 to 0.8639
Hazard Ratio
 Ratio 3.446
 95% CI of ratio 2.176 to 5.456
This table was obtained by using GraphPad Prism software 7.04. 
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rate of patients with higher expression of caspase-4 in 
the tumor mass was three-fold decreased than patients 
with lower expression (0.92 vs 3.03 years) (Figure 5 and 
Table 6), implying that the levels of this protein in the 
tumor mass could represent not only a diagnostic tool 
but also a prognostic biomarker, opening new therapeutic 
perspective for NSCLC patients. 
Another important issue to be pointed out is the 
higher presence of caspase-4 in the blood of smokers and 
COPD patients. It is well known that smoking represents 
the highest risk factor for lung cancer [11]. In our study 
we found that 70% of smokers and COPD patients were 
positive to the circulating caspase-4. Although we do 
not have a follow-up in the likelihood evidence of lung 
cancer for these subjects and patients, it is likely that the 
higher levels of the circulating caspase-4 compared to 
healthy subjects are predictive for a high risk of lung 
malignancy. It has to be noted though, that as already 
published, the environmental pollution together smoking 
is another risk factor for lung cancer. Indeed, we found 
that smokers- and COPD-derived PBMCs treated 
with air pollutants [24, 25], such as particulate matter 
(PM) of ultrafine sizes, were able to release caspase-4, 
index of higher risk for lung cancer establishment. A 
great limitation to this study is the absence of follow-
up information about COPD and healthy smokers, in 
order to better understand and associate the levels of 
the circulating caspase-4 to the establishment of a tumor 
mass, avoiding late diagnosis.
In conclusion, in this study we propose the 
circulating and tumor-associated caspase-4 as a 
diagnostic biomarker for NSCLC that can be detected 
in both blood (in a non-invasive manner) and tissues 
with high sensitivity/true positive values compared to 
what so far described in the literature. It is more specific 
than currently available biomarkers (i.e. CA-9, CA-12.2, 
CEA), common to many non-neoplastic pathologies, and 
very importantly, it is related to the identification of a 
protein rather than DNA/RNA signature. In addition, 
tumor-associated caspase-4 has a prognostic value, 
opening new therapeutic perspectives for NSCLC 
patients. 
MATERIALS AND METHODS
Human samples 
The patients in this study were diagnosed with 
operable NSCLC (stage IA-IB, n = 79; Stage IIA-IIB, 
n = 34; Stage IIIA-IV, n = 12), and underwent surgical 
resection at Ospedale dei Colli, AORN, Monaldi, Naples, 
Italy, during the period 2014–2017. Clinical data were 
obtained from questionnaires and histology reports from 
the Pathological Anatomy Unit of the hospital. The 
project was approved by the institutional review board 
and by the Ethical Committee (approval number for lung 
cancer patients 1254/2014). Similarly, COPD-derived 
samples (only blood) were obtained after the approval 
of the institutional review board and Ethical Committee 
(approval number 11/2017). Blood from healthy non-
smokers and smoker subjects were obtained by the same 
Unit at Ospedale dei Colli, AORN, Monaldi, Naples, 
Italy, when possible, and by “casa di Cura La Quiete”, 
Salerno, Italy, in collaboration (approval, 19.12.2016) 
with Immune Pharma S.r.l. Blood from healthy (smoker 
and non-smoker) subjects, COPD, lung cancer patients 
was collected after oral and written information provided 
by the MDs, and signed a written consent form before 
entering the project. EDTA-blood was obtained prior to 
surgery, in case of lung cancer patients. 
Healthy (smoker and non-smoker) subjects were 40 
± 10 (mean ± S.E.M) years of age; COPD and lung cancer 
patients were 60 ± 10 (mean ± S.E.M) years of age. COPD 
and lung cancer patients were smokers or former smokers, 
whereas healthy subjects were divided in Smokers and 
Non-smokers. 
Blood was withdrawn and collected and used within 
24 hours. 
ELISA 
The presence of the soluble caspase-4 was detected 
by means of ELISA, one of the technology patented 
by ImmunePharma S.r.l. (RM2014A000080 and PCT/
IB2015/051262) (Department of Pharmacy, University 
of Salerno, Italy). The ELISA kit was based on custom 
antibodies, projected by the ImmunePharma S.r.l., and 
that are not currently commercially available. The test was 
performed on plasma and collagenase I (1 U/ml) digested 
lung tissues.
Statistical analysis 
Results are expressed as median ± interquartile range. 
One Way ANOVA, followed by Bonferroni’s post test, 
and/or Mann–Whitney test were used where appropriate. 
Percent survival was estimated by means of Kaplan–Meier 
method and compared with a non-parametric log-rank test. 
Percent survival was calculated from the time of surgical 
resection. The survival rate was calculated for 73 patients 
whose tissue-derived biological samples could be tested by 
means of ImmunePharma’s ELISA kit. p values less than 
0.05 were considered significant. 
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